Kaposi's sarcoma: Advances in tumor biology and pharmacotherapy

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 670-683

  Sung, Jennifer C Y ^a   Louie, Stan G ^a   Park, Sunny Y ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BLEOMYCIN; CHORIONIC GONADOTROPIN; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PACLITAXEL; PENTOXIFYLLINE; PICRIC ACID; POLYSACCHARIDE SULFATE; RECOMBINANT THROMBOCYTE FACTOR 4; RETINOID; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; DRUG MECHANISM; HUMAN; KAPOSI SARCOMA; PATHOGENESIS; REVIEW; VASCULARIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EUROPE, EASTERN; HUMANS; MEDITERRANEAN REGION; RADIOTHERAPY; SARCOMA, KAPOSI;

EID: 0030756275     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993;28:371-95.
2. Pluda JM, Parkinson DR, Fiegal E, et al. Non-cytotoxic therapeutic approaches to the treatment of HIV associated Kaposi's sarcoma. Oncology 1993;7:25-33.
3. Martin RW, Hood AF, Farmer ER. Kaposi's sarcoma. Medicine 1993;72:245-61.
4. Lilenbaum RC, Ratner L. Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 1994;8:141-51.
5. Krown SE, Myskowski P, Paredes J. Kaposi's sarcoma. Med Clin North Am 1992;76:235-52.
6. Steis RG, Longo DL. Clinical, biologic, and therapeutic aspects of malignancies associated with the acquired immunodeficiency syndrome. Ann Allergy 1988;60:310-23.
7. Volberding PA. Kaposi's' sarcoma and the acquired immune deficiency syndrome. Med Clin North Am 1986;70:665-75.
8. Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:744-50.
9. Groopman JE. Biology and therapy of epidemic Kaposi's sarcoma. Cancer 1987;59:633-7.
10. Hutt MSR. The epidemiology of Kaposi's sarcoma. Antibiot Chemother 1981;29:3-11.
11. Penn I. Kaposi's sarcoma in immunosuppressed patients. J Clin Lab Immunol 1983;12:1-10.
12. Klepp O, Dahl O, Stenwig JT. Association of Kaposi's sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi's sarcoma in Norway. Cancer 1978;42:2626-30.
13. Myers BR, Kessler E, Levi J, et al. Kaposi's sarcoma in kidney transplant recipients. Arch Intern Med 1974;133:307-11.
14. Zisbrod Z, Haimov M, Schanzer H, et al. Kaposi's sarcoma after kidney transplantation: report of complete remission of cutaneous and visceral involvement. Transplantation 1980;30:383-4.
15. Tebbe B, Mayer-da-Silva A, Garbe C, et al. Genetically determined coincidence of Kaposi's sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment: spontaneous regression 8 months after discontinuing therapy. Int J Dermatol 1991;30:114-20.
16. Rutherford GW, Schwarcz SK, Lemp GF, et al. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J Infect Dis 1989;159:569-72.
17. Rutherford GW, Payne SF, Lemp GF. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J Acquir Immune Defic Syndr 1990;3(suppl 1):S4-7.
18. Haverkos GW, Dritnab DP. Prevalence of Kaposi's sarcoma among patients with AIDS [letter]. N Engl J Med 1985;312:1518.
19. Ensoli B, Barillari G, Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:281-95.
20. Sinkovics JG. Kaposi's sarcoma: its "oncogenes" and growth factors. Crit Rev Oncol Hematol 1991;11:87-107.
21. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi's sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87:4068-72.
22. Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-6.
23. Salahuddin SZ, Nakamura S, Biberfeld P, et al. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 1989;242:430-3.
24. Miles SA, Martinez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 1992;255:1432-4.
25. Nair BC, Devico AL, Nakamura S, et al. Identification of a major growth factor for AIDS Kaposi's sarcoma derived cells as oncostatin M. Science 1992;255:1430-2.
26. Nakamura S, Sakurada S, Salahuddin SZ, et al. Inhibition of development of Kaposi's sarcoma related lesions by a bacterial cell wall complex. Science 1992;255:1437-40.
27. Vogel J, Hinrichs SH, Reynolds RK, et al. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988;335:606-11.
28. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
29. Lunardi Iskandar Y, Bryant JL, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995;375:64-8.
30. Krown SE, Metroka C, Wernz JC, et al. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol 1989;7:1201-7.
31. Spittle MF. A simple and effective treatment for AIDS related Kaposi's sarcoma. Br Med J 1987;295:248-9.
32. Holecek MJ, Harwood AR. Radiotherapy of Kaposi's sarcoma. Cancer 1978;41:1733-8.
33. Berson AM, Quivey JM, Harris JW, et al. Radiation therapy for AIDS-related Kaposi's sarcoma. Int J Radiat Oncol Biol Physiol 1990;19:569-75.
34. Cooper JS, Fried PR, Laubenstein LJ. Initial observations of the effect of radiotherapy on epidemic Kaposi's sarcoma. JAMA 1984;252:934-5.
35. Volberding PA. The role of chemotherapy for epidemic Kaposi's sarcoma. Semin Oncol 1987;14(suppl 3):23-6.
36. Volberding PA, Abrams DI, Conant M, et al. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
37. Klein E, Schwartz RA, Laor Y, et al. Treatment of Kaposi's sarcoma with vinblastine. Cancer 1980;45:427-31.
38. Sloan AJ, Greenwald ES, Silvay O, et al. Long-term complete remissions of Kaposi's sarcoma with vinblastine therapy. Cancer 1981;47:637-9.
39. Mintzer DM, Real FX, Jovino L, et al. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985;102:200-2.
40. Laubenstein LJ, Krigel RL, Odajnnyk CM, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 1984;2:1115-20.
41. Lassoued K, Clauvel JP, Katlama C, et al. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 1990;66:1869-72.
42. Fischl MA, Krown SE, O'Boyle KP, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1993;6:249-64.
43. Saville MW, Lietzau J, Wilson W, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346(8966):26-8.
44. Gelmann EP, Longo D, Lane HC, et al. Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am J Med 1987;82:456-62.
45. Gill PS, Rarick MU, Espina B, et al. Advanced acquired immune deficiency syndrome-related Kaposi's sarcoma: results of pilot studies using combination chemotherapy. Cancer 1990;65:1074-8.
46. Gill PS, Rarick M, McCutchan A, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
47. Gill P, Rarick M, Bernstein-Singer M, et al. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990;13:315-19.
48. Masood R, Husain SR, Rahman A, Gill P. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS Res Hum Retroviruses 1993;9:741-6.
49. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20.
50. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64.
51. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996-1003.
52. Brambilla L, Boneschi V, Beretta G, et al. Intralesional chemotherapy for Kaposi's sarcoma. Dermatologica 1984;169:150-5.
53. Epstein JB, Lozada-Nur F, McLeod WA, et al. Oral Kaposi's sarcoma in acquired immunodeficiency syndrome: review of management and report of the efficacy of intralesional vinblastine. Cancer 1989;64:2424-30.
54. Epstein JB. Treatment of oral Kaposi's sarcoma with intralesional vinblastine. Cancer 1993;71:1722-5.
55. Boudreauxet AA, Smith LL, Cosby CD, et al. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome: a clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993;28:61-5.
56. Mitsuyasu RT. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 1991;79(suppl 1):69-73.
57. Krown SE. Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:311-22.
58. Wadler S. The role of interferons in the treatment of solid tumors. Cancer 1992;70:949-58.
59. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alfa-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-6.
60. Gelmann EP, Preble OT, Lane HC, et al. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical response and prognostic parameters. Am J Med 1985;78:737-41.
61. Rios A, Mansell PWA, Newell GR, et al. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 1985;3:506-12.
62. Krown SE, Real FX, Vadhan-Raj S, et al. Kaposi's sarcoma and the acquired immune deficiency syndrome: treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 1986;57:1662-5.
63. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-51.
64. Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer 1987;59:620-5.
65. Groopman JE, Scadden DT. Interferon therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110:335-7.
66. Lane HC, Darvey V, Kovacs JA, et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. Ann Intern Med 1990;112:805-11.
67. Evans LA, Itri LM, Campion M, et al. Interferon-α2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 1991;10:39-50.
68. Krigel RL, Slywotzky CM, Lonberg M, et al. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-α2b and etoposide. J Biol Response Mod 1988;7:359-64.
69. Gill PS, Rarick MU, Berstein-Singer M, et al. Interferon-alpha maintenance therapy after cytotoxic chemotherapy for treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Biol Response Mod 1990;9:512-16.
70. Shepherd FA, Evans WK, Garvey B, et al. Combination chemotherapy and α-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome. Can Med Assoc J 1988;139:635-9.
71. Mitsuyasu RT, Taylor JM, Glaspy J, et al. Heterogeneity of epidemic Kaposi's sarcoma: implications for therapy. Cancer 1986;57:1657-61.
72. Hartshorn KL, Vogt MW, Chow TC, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha-A interferon. Antimicrob Agents Chemother 1987;31:168-72.
73. Fischl MA. Anti-retroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma. Am J Med 1991;90(suppl 4A);2S-7.
74. Kovacs JA, Deyton L, Davey R, et al. Combined zidovudine and interferon-å therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:280-7.
75. Stadler R, Bratzke B, Schaart F, Orfanos C. Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi's sarcoma: clinical consequences and side effects. J Invest Dermatol 1990;95:170S-5.
76. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:812-21.
77. Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991;9:802-8.
78. Davey RT, Davey V, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-α, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type I infection. J Infect Dis 1991;164:43-52.
79. Krown SE, Paredes J, Bundow D, et al. Interferon-α, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-51.
80. Miles SA, Wang H, Cortes E, et al. Beta-interferon therapy in patients with poor-prognosis Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:582-9.
81. Krigel RL, Odajnyk CM, Laubenstein LJ, et al. Therapeutic trial of interferon-γ in patients with epidemic Kaposi's sarcoma. J Biol Response Mod 1985;4:358-64.
82. Volberding P, Moody DJ, Beardslee D, et al. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24.
83. Krigel RL Padavic-Shaller KA, Rudolph AR, et al. Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and b-interferon: results of a phase 2 study. J Biol Response Mod 1989;8:359-65.
84. Robertson PA, Ross HJ, Figlin RA. Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma. Ann Intern Med 1989;111:682-4.
85. Aboulafia D, Miles SA, Saks SR, et al. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1989;2:54-8.
86. Kahn JO, Kaplan LD, Volberding PA, et al. Intralesional recombinant tumor necrosis factor-α for AIDS-associated Kaposi's sarcoma: a randomized double-blind trial. J Acquir Immune Defic Syndr 1989;2:217-23.
87. Billington DC. Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Des Discov 1991;8:3-35.
88. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans-retinoic acid). N Engl J Med 1981;324:1385-93.
89. Sidell N, Taga T, Hiraro T, et al. Retinoic acid induced growth inhibition of a human myeloma cell line via down regulation of IL-6 receptors. J Immunol 1991;146:3809-14.
90. Cornell J, Rapaport E, Richman DD, et al. Anti-proliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest 1994;93:1981-6.
91. Bonhomme L, Fredj G, Maurisson G, et al. Systemic treatment of AIDS associated Kaposi's sarcoma (KS) with all-trans retinoic acid (ATRA). Int Conf AIDS 1993;9:395.
92. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13:1966-74.
93. Kahn J, Ruiz R, Kerschmann R, et al. A phase 1/2 study ot recombinant platelet factor 4 (rPF4) in patients with AIDS-related Kaposi's sarcoma (KS). Proc Annu Meet Am Soc Clin Oncol 1993;12:A4.
94. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
95. Staddon A, Henry D, Bonnem E. A randomized dose finding study of recombinant platelet factor 4 (rPF4) in cutaneous AIDS-related Kaposi's sarcoma. Proc Annu Meet Am Soc Clin Oncol 1994;13:A3.
96. Miles S, Rezai A, Martinez-Maza O, et al. Recombinant platelet factor 4 (rPF4) and a non-heparin binding derivative inhibit AIDS-Kaposi sarcoma derived cell lines. Int Conf AIDS 1991;7:108.
97. Wellstein A, Zugmaier G, Califano JA, et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 1991;83:716-20.
98. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
99. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-46.
100. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 1989;143:1851-8.
101. Louie S, Cai J, Law R, et al. Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi s sarcoma. J Acquir Immune Defic Syndr Hum Retroviral 1995;8:455-60.
102. Fazely F, Dezube BJ, Allen RJ, et al. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991;77:1653-6.
103. Gill PS, Lunardi-Iskandar Y, Louie SG, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9.